You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable Hepatocellular Carcinoma (HCC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Non-resectable Trial in Belgium, Germany, Italy (BioPearl™)

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • BioPearl™
  • Brussels, Belgium
  • +5 more
Jun 20, 2023

Unresectable Hepatocellular Carcinoma (HCC) Trial in Milano, Rozzano, Barcelona (NMS-01940153E)

Recruiting
  • Unresectable Hepatocellular Carcinoma (HCC)
  • Milano, Italy
  • +2 more
Dec 2, 2022

Hepatocellular Carcinoma Trial (AK112)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Jun 24, 2022

Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer Trial in Grafton (Eye90 Microspheres)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Eye90 Microspheres
  • Grafton, New Zealand
    Auckland District Health Board
Jan 30, 2023

Hepatocellular Carcinoma Trial in United States (Y-90 TARE, Atezolizumab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Y-90 TARE
  • +2 more
  • Washington, District of Columbia
  • +5 more
Jan 18, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • M-TACE
  • Shanghai, Shanghai, China
    Department of Interventional Radiology, Zhongshan Hospital, Fuda
May 24, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, sintilimab plus SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023

Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Oligometastatic Disease
  • SBRT plus tislelizumab and regorafenib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2023

Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib Plus Tislelizumab
  • Transarterial Chemoembolization(TACE)
  • Beijing, Beijing, China
    Nan Zhang
Apr 22, 2023

Carcinoma, Hepatocellular Trial in India (Lenvatinib)

Recruiting
  • Carcinoma, Hepatocellular
  • Bangalore, Karnataka, India
  • +10 more
Feb 1, 2023

Hepatocellular Carcinoma Trial in Louisville (TheraSphere HUD)

Completed
  • Hepatocellular Carcinoma
  • TheraSphere HUD
  • Louisville, Kentucky
    University of Louisville Hospital / Norton Hospital
Dec 12, 2021

Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC) Trial in France, Spain, United

Recruiting
  • Unresectable Hepatocellular Carcinoma (HCC)
  • Liver Metastases From Colorectal Cancer (mCRC)
  • SIRT
  • Clichy, Cedex, France
  • +8 more
Jul 31, 2023

Hepatocellular Carcinoma Trial in Guangzhou (TACE-HACI, plus atezolizumab-bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • TACE-HACI, plus atezolizumab-bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma Trial in Ann Arbor (drug, device, radiation, diagnostic

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Dec 16, 2021

Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial (RP3,

Not yet recruiting
  • Locally Advanced Hepatocellular Carcinoma
  • +2 more
  • RP3
  • +2 more
  • (no location specified)
Feb 8, 2023

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Hepatocellular Carcinoma Trial in Tianjin (Icaritin, Huachansu)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Oct 24, 2022

Malignant Biliary Obstruction, Hepatocellular Carcinoma Trial in Seoul (Endoscpic biliary drainage using fully covered metal

Recruiting
  • Malignant Biliary Obstruction
  • Hepatocellular Carcinoma
  • Endoscpic biliary drainage using fully covered metal stent
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 14, 2023

Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)

Recruiting
  • Macrotrabecular Massive Hepatocellular Carcinoma
  • HAIC
  • Camrelizumab plus Apatinib
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023

Hepatocellular Carcinoma Trial in Seoul (Durvalumab, Radioembolization)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 23, 2021

Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)

Recruiting
  • Hepatocellular Carcinoma
  • cTACE
  • +2 more
  • Nanjing, Jiangsu, China
    Zhongda Hospital, Southeast University
Jul 22, 2022

Hepatocellular Carcinoma Trial (HAIC(FOLFOX), Oxaliplatin, Leucovorin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • HAIC(FOLFOX)
  • +5 more
  • (no location specified)
Aug 16, 2022

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (TACE combined with lenvatinib and sintilimab)

Completed
  • Hepatocellular Carcinoma Non-resectable
  • TACE combined with lenvatinib and sintilimab
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Nov 8, 2022